Industry Liaison Forum

The ILF highlights the perspective of the HIV biomedical industry and catalyses multi-stakeholder dialogue, engagement and actions to address barriers along the HIV cascade and cross-cutting issues.

The work of the ILF is guided by a strong, multi-stakeholder advisory group, which is composed of industry and non-industry representatives.

The ILF focuses on three areas:

  • Collaboration platform
  • Paediatric HIV
  • Regulatory affairs.

Learn more here.


Latest Activities



ILF Annual Report 2016

See how we facilitate the full contribution of the biomedical industry to the HIV response.

Download the annual report

ILF/CIPHER Webinar: Report back from PADO 3

The ILF and CIPHER, in collaboration with WHO, held a webinar on 28 February 2017 to disseminate the main outcomes from the Paediatric ARV Drug Optimization (PADO) 3 meeting - which took place during the Geneva Paediatrics Week in December 2016. The webinar also included an update from the Paediatric ARV Working Group (PAWG).

The webinar was focused on ensuring ARV manufacturers are kept informed of the latest developments in the paediatric ARV field. It followed from another webinar to report back from the paediatric week which the ILF and CIPHER held in December 2016 (watch the recording here).

Watch the webinar

ILF/CIPHER Webinar: Report back from the paediatrics week

The ILF and CIPHER held a webinar on 15 December 2016 to disseminate, beyond stakeholders directly involved, the main outcomes of the Geneva paediatrics HIV week “Making the right drugs available for children with HIV”. Specifically, the webinar was focused on ensuring ARV manufacturers are kept informed of the latest developments in the paediatric ARV field.

Watch the webinar

CTA/ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Fast tracking development of priority formulations

The ILF and CIPHER, with the Global Pediatric Antiretroviral Commitment-to-Action (CTA) partner organizations, recently convened a workshop to discuss a new framework of collaboration for accelerating the development of the most-needed paediatric antiretroviral (ARV) drugs.

The workshop built on previous discussions around developing a global accelerator for paediatric formulations, a collaborative framework potentially supported by an innovative financing mechanism, to fast track development of paediatric ARVs. This type of collaborative framework could also serve as a model for tuberculosis and other disease areas.

In the context of existing broader constraints to paediatric ARV development, stakeholders also agreed on the need for a range of actions, including:

  • Reviewing the current age-staggered approach for development of new products in order to include adolescents in initial (registrational) adult efficacy trials and promote simultaneous enrolment of children in different age groups
  • Developing age-appropriate paediatric formulations earlier in the process of testing new drugs in adults in order to minimize the paediatric formulation development and approval timelines
  • More systematic coordination between regulators, industry and research networks during the development and review of paediatric implementation plans (PIPs) and pediatric study plans (PSPs)
  • Simplifying the PIP/PSP modification processes
  • Encouraging other regulators to recognize and act on Paediatric ARV Drug Optimization (PADO) priorities to speed up in-country introduction
  • Improving the collaboration and alignment between regulatory authorities
  • Increasing information sharing, especially for PADO deliberations, to industry and regulators
  • Exploring alternative options to leverage generic industry engagement and potentially provide assistance to PIPs/PSPs
  • Developing incentives to stimulate paediatric formulation development by targeting the steps of biggest concern (i.e., financing clinical trials, in-country registration, demand creation and consolidation).

Stakeholders agreed that the proposed framework could be a useful mechanism for supporting faster paediatric ARV development. Industry representatives noted that while lack of funds to develop paediatric ARVs may not be the only limitation as long as drugs are purchased once developed, financial support may be required for other steps in the cascade from research to development to introduction. To that end, further discussion is needed to fully articulate what the funding would support.

Download the meeting report

ILF Thematic Roundtable on HIV Diagnostics

The improvement of early infant diagnosis (EID) through the implementation of point-of-care (POC) diagnostics has been identified as an important contribution to achieving the first of the three 90s of the UNAIDS 90-90-90 goals (HIV diagnosis) among HIV-exposed infants, and therefore also to achieving the other 90s goals. This meeting provided an opportunity to review the progress made in optimizing EID testing and securing and improving patients’ and caregivers’ access to quality EID and POC diagnostics. These elements are essential to improving subsequent paediatric care and treatment for HIV-infected infants in low- and middle-income countries.

The two key take-home messages from this interactive discussion are:

  • Scaling up POC EID now – There is an urgent need for rapid implementation of the available POC EID platforms. Planned, individual country evaluations are unnecessary, and current efforts should focus on rapid implementation programmes. Impact evaluations should similarly inform the best use and placement of POC EID systems.
     
  • Investing in QA – All actors – funders, ministries of health, health care professionals and implementers – should consider QA for POC as an investment, not a cost. QA should become an integral part of all POC diagnostics programmes.

Download the meeting report

How to meet the first-ever global hepatitis targets

Blog post by Sébastien Morin, Eliot Ross Albers and Jürgen Rockstroh

HCV has historically been under-estimated, under-prioritized and under-resourced in comparison to the significant impact it has on millions of people around the world. However, with the adoption of the global hepatitis targets this is changing and an HCV-free generation, where the disease is no longer a great public health concern, is on the horizon.

Read the full post

Modern HIV prevention: what’s next for women?

Blog post by Lisa Levin, Cate Hankins, Brent Allan, Rahab Mwaniki, Nelli Bazarova, Sébastien Morin, and Linda-Gail Bekker

Today, some of the world’s leading scientists and researchers were gathered in Boston at the Conference on Retroviruses and Opportunistic Infections (CROI). “What’s next for women?” was the question on the minds of many, after results were released from two trials that looked at one of the most promising new HIV prevention tools of our time: the long-acting dapivirine vaginal ring, a female-controlled HIV prevention method that could potentially protect women for up to a month at a time.

Read the full post

ILF Corporate Partners



See the list of previous industry partners   |   Learn about the ILF Corporate Partnership Programme